ReviewViruses2021
Human Papilloma Virus Vaccination.
Review in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- The global detection rate of human papillomavirus DNA in ovarian cancer: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Pooled it
- Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.Journal of neurology · 2022Pooled it
- Family Physicians' Knowledge Levels and Awareness Regarding HPV Infection and HPV Vaccines.Healthcare (Basel, Switzerland) · 2026Article
- Human Papillomavirus: Update in Bridging Basic Science to Clinical and Public Health Innovations.Health science reports · 2026Article
- Effect of coriolus versicolor-based vaginal gel on clearance of human papillomavirus and cervical dysplasia - a scoping review.BMC women's health · 2026Article
- HPV Vaccine: An Effective but Underutilized Prevention Tool.International journal of environmental research and public health · 2025Article
- Preventive insights and practices of female health professionals regarding cervical cell dysplasia: a cross-sectional study in Egypt.BMC public health · 2025Article
- Rural-urban variations in cervical cancer screening uptake among women in Ghana: Evidence from the 2022 Ghana Demographic and Health Survey.BMC women's health · 2025Article
- Age-related distribution of human papillomavirus genotypes in women with cervical squamous cell carcinoma from Linyi, China, 2015-2023.Virology journal · 2025Article
- Review
- Analyzing HPV Vaccination Service Preferences among Female University Students in China: A Discrete Choice Experiment.Vaccines · 2024Article
- Cervical cancer screening among women with comorbidities: evidence from the 2022 Tanzania demographic and health survey.BMC public health · 2024Article
- Screening for High-Risk Human Papillomavirus Reveals HPV52 and HPV58 among Pediatric and Adult Patient Saliva Samples.Dentistry journal · 2024Article
- Fractional view analysis of sexual transmitted human papilloma virus infection for public health.Scientific reports · 2024Article
- Article
- Knowledge of HPV and HPV Vaccination among Polish Students from Medical and Non-Medical Universities.Vaccines · 2023Article
- Association of naturally acquired type-specific HPV antibodies and subsequent HPV re-detection: systematic review and meta-analysis.Infectious agents and cancer · 2023Review
- Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect.Infectious agents and cancer · 2023Review
- Nurses and doctors 's awareness and knowledge towards treatment and care of cervical cancer patients: a cross-sectional study.BMC nursing · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papilloma virus (HPV) is the most common sexually transmitted infection worldwide causing a variety of benign and malignant conditions. A significant portion of the global population is infected with HPV, with the virus attributed to causing up to 5% of cancers worldwide. Bivalent, quadrivalent, and nine-valent vaccinations exist to aid in the prevention of these diseases and have been proven to be effective at preventing both benign and malignant disease. While vaccination is readily accessible in more developed countries, barriers exist to worldwide distribution and acceptance of vaccination. Vaccination and screening of HPV infection when used in combination are proven and predicted to decrease HPV related pathology. Improvements in vaccination formulations, for treatment as well as prevention, are actively being sought from a variety of mechanisms. Despite these advancements, and the data supporting their efficacy, there has been substantial delay in obtaining adequate vaccination coverage. In reviewing these challenges and looking forward to new vaccine development-especially within the current pandemic-it is clear from the challenges of HPV we require methods to more effectively encourage vaccination, ways to dispel vaccination myths as they occur, and implement better processes for vaccine distribution globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.